Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 84 of 2459…nd 2024. Eligible patients had a diagnosis of cancer (including melanoma, squamous cell carcinoma, basal cell carcinoma, Merkel cell car…
… analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. The Journal of Pathology. 2007;213(4):392–401.Su C, Lv Y, Lu W…
…aintenance therapy (MT) consisting of mercaptopurine (6-MP) and methotrexate (MTX). Evidence suggests promising clinical outcomes from the u…
…age small cell lung cancer. Oncologist 2021;26:433-8.Imdelltra (tarlatamab). Full Prescribing Information, Amgen Inc, Thousand Oaks, CA, U…
…d preferable drug developability and mouse PK profile. In vivo, ES038 treatment reduced leukemic tumor growth and extended mice survi…
…int blockades have emerged as major therapies for patients with lung adenocarcinoma. However, there may still be a group of patients with advanced …
…W, Schlom J, Gulley J. 616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Re…
…number: NCT06865521).All patients were recruited and treated at West China Hospital of Sichuan University, where the study protocol was approved by the Institutional Rev…
…ill be enrolled in the dose-escalation cohorts and administered STC-15 orally thrice weekly (TIW) at 3 escalating dose levels in combi…
…oxygenation strategies remain limited for clinical translation. NanO 2 (NuvOx Pharma), a novel perfluorocarbon-based oxygen therapeuti…
…vec (RP1; an HSV-1-based oncolytic immunotherapy) combined with nivolumab demonstrated clinically meaningful, durable antitumor activity …